Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31798 total
Chip stocks are drawing the heaviest options flow ahead of a packed earnings season. Micron Technology leads both the bearish and bullish options rankings this week. The stock has risen 266% year to date. Traders…
PepsiCo kicks off the week today. The beverages and snacks giant reports Q3 2026 results before the open. A follow-up earnings call from Helen of Troy also runs today. Tomorrow, Delta Air Lines holds its Q3 earnings…
Citigroup's analysts cut price targets across at least six names on Thursday, sweeping from defence contractors to freight carriers and specialty chemicals. The sharpest defence move hit LDOS. Analyst John Godyn…
Kenneth Bryan Dart, the main shareholder of EVO, filed in late August that he bought over 10 million shares in the Swedish gaming infrastructure company across two days in late July. The total outlay was $716 million.…
Short sellers made their biggest move of the week into MMED. MiniMed Group's short interest jumped to 91% of free float as of October 6, up from 74.5% just seven days earlier. That 16.5 percentage point weekly rise is…
Applied Digital closes out a rough month heading into its October 9 earnings release, down 10% in the past 30 days to $23.81 and off a further 6% on Wednesday alone. Short sellers have not blinked. Short interest holds…
Q3 earnings season begins in earnest this week. Wells Fargo, Goldman Sachs, and Citigroup all report Monday. UnitedHealth Group prints the same day, a closely watched result given Medicare Advantage penetration hit a…
Options flow is sending a divided signal heading into earnings season. Rails and industrials are drawing exclusively bullish bets. Semiconductors are absorbing the heaviest put volume on the board. Union Pacific, CSX…
The Q3 earnings season hits its stride this week. Several of Wall Street's biggest names report between Tuesday and Friday. PepsiCo kicks things off today, reporting Q3 2026 results before the open. The beverage and…
Japan's machine tool orders delivered the sharpest annual rise this cycle in August 2026. According to the Japan Machine Tool Builders' Association, total orders reached JPY 197,867m, up 64.7% on August 2025. Foreign…
Citigroup delivered a broad sweep of target price reductions on Thursday, hitting defence, transportation, and chemicals in a single session. The deepest cut fell on NSC. Citigroup analyst Ariel Rosa trimmed the…
UBER President and COO Andrew Gordon MacDonald filed two open-market purchases on September 8, disclosing trades executed on September 4. Combined, the two buys total $5.3 million, split across 54,325 shares at roughly…
Short sellers moved aggressively into MMED this week. The medical device company saw its short interest jump to 91% of free float from 74.5% just seven days ago. That is a 16.5 percentage point rise. The ORTEX short…
The dominant story this week is a sharp pivot into actively managed ETFs. Active strategies pulled in $76.8B in net flows over the past week. That dwarfs vanilla passive products, which added just $6.0B. Over the…
GRPN sits at one of the most contested intersections in small-cap retail: a stock with 31% of its float sold short, an active 13D filer on the register, and options traders positioned more bullishly than at almost any…
JSW enters the final stretch before its November 24 results with multiples at distressed levels, a borrow market that has loosened materially since August, and a short score that has held stubbornly elevated despite…
Nebius Group heads into the week with a striking split: the stock is up 7.4% on Tuesday alone and 5.3% on the week to $249.87, yet the COO sold roughly $90 million of stock on Monday and the short base has not…
WEN enters its November earnings window with a rare alignment of pressures: a stock down 23% in a month, short interest near one-quarter of the free float, and an activist on the register who has so far been unable to…
Iovance Biotherapeutics is pulling back from its September highs, down 10% on the week to $12.96, as the slow-motion short unwind continues and the Street reassesses what the commercial ramp is worth at this…
FITB has stabilised at $51.00 this week, but the calm on the surface masks a more interesting set of cross-currents heading into Q3 results on October 19. A note published earlier today covered the analyst…
